文献速递前列腺癌

局部治疗改善转移性前列腺癌生存

Local Therapy Improves Survival in Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol · 2017-04-03

在监测、流行病学和最终结果数据库(2004-2013年)13 692例转移性前列腺癌患者中,474例接受局部治疗(313例根治性前列腺切除术,161例放疗),倾向性评分匹配后局部治疗较未局部治疗降低肿瘤特异性死亡(SHR 0.40,95%CI 0.32-0.50),根治性前列腺切除术较放疗降低肿瘤特异性死亡(SHR 0.59,95%CI 0.35-0.99)。

要点

  • 倾向性评分匹配后局部治疗(n=474)较未局部治疗(n=1896)降低肿瘤特异性死亡,SHR 0.40(95%CI 0.32-0.50)。
  • 倾向性评分匹配后根治性前列腺切除术(n=161)较放疗(n=161)降低肿瘤特异性死亡,SHR 0.59(95%CI 0.35-0.99)。
  • Gleason评分≤7、临床分期≤cT3和M1a亚期患者从局部治疗及根治性前列腺切除术中获益最大。

核心结论

  • 在转移性前列腺癌中,局部治疗较未局部治疗降低肿瘤特异性死亡。
  • 在局部治疗中,根治性前列腺切除术较放疗降低肿瘤特异性死亡。
  • Gleason评分≤7、临床分期≤cT3和M1a亚期患者从局部治疗及根治性前列腺切除术中获益最大。
  • 作者认为在正在进行的临床试验确认所提出的获益之前,考虑研究局限性很重要。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库(2004-2013年)的回顾性研究,纳入13 692例转移性前列腺癌患者,其中474例接受局部治疗(313例根治性前列腺切除术,161例放疗),其余接受未局部治疗。
  • 采用多变量竞争风险回归分析,在倾向性评分匹配后比较未局部治疗与局部治疗、根治性前列腺切除术与放疗的肿瘤特异性死亡,并辅以交互作用、敏感性、未测量混杂因素和landmark分析。

主要发现

  • 13 692例转移性前列腺癌患者中,474例接受局部治疗:313例根治性前列腺切除术,161例放疗。
  • 多变量竞争风险回归分析倾向性评分匹配后,局部治疗(n=474)较未局部治疗(n=1896)肿瘤特异性死亡更低(SHR 0.40,95%CI 0.32-0.50)。
  • 多变量竞争风险回归分析倾向性评分匹配后,根治性前列腺切除术(n=161)较放疗(n=161)肿瘤特异性死亡更低(SHR 0.59,95%CI 0.35-0.99)。
  • 肿瘤特异性死亡率最低见于Gleason评分≤7、临床分期≤cT3和M1a亚期患者。
  • 交互作用和敏感性分析证实结果稳健,landmark分析排除了偏向局部治疗的偏倚;一个影响30%未局部治疗患者的强未测量混杂因素(HR=5)可能消除局部治疗获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据为回顾性。
  • 一个影响30%未局部治疗患者的强未测量混杂因素(HR=5)可能消除局部治疗获益。
  • 作者认为在正在进行的临床试验确认所提出的获益之前,考虑研究局限性很重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of the primary, termed local therapy (LT), may improve survival in metastatic prostate cancer (mPCa) versus no local therapy (NLT). OBJECTIVE: To assess cancer-specific mortality (CSM) after LT versus NLT in mPCa. DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology and End Results database (2004-2013), 13 692 mPCa patients were treated with LT (radical prostatectomy [RP] or radiation therapy [RT]) or NLT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable competing risk regression analyses (MVA CRR) tested CSM after propensity score matching (PSM) in two analyses, (1) NLT versus LT and (2) RP versus RT, and were complemented with interaction, sensitivity, unmeasured confounder, and landmark analyses. RESULTS AND LIMITATIONS: Of 13 692 mPCa patients, 474 received LT: 313 underwent RP and 161 RT. In MVA CRR, after PSM, LT (n=474) results in lower CSM (subhazard ratio [SHR] 0.40, 95% confidence interval [CI] 0.32-0.50) versus NLT (n=1896). In MVA CRR after PSM, RP (n=161) results in lower CSM (SHR 0.59, 95% CI 0.35-0.99) versus RT (n=161). Invariably, lowest CSM rates were recorded for Gleason ≤7, ≤cT3, and M1a substage. Interaction and sensitivity analyses confirmed the robustness of results, and landmark analyses rejected the bias favouring LT. A strong unmeasured confounder (HR=5), affecting 30% of NLT patients, could obliterate LT benefit. Data were retrospective. CONCLUSIONS: In mPCa, LT results in lower mortality relative to NLT. Within LT, lower mortality is recorded after RP than RT. Patients with most favourable grade, local stage, and metastatic substage derive most benefit from LT. They also derive most benefit from RP, when LT types are compared (RP vs RT). It is important to consider study limitations until ongoing clinical trials confirm the proposed benefits. PATIENT SUMMARY: Individuals with prostate cancer that spreads outside of the prostate might still benefit from prostate-directed treatments, such as radiation or surgery, in addition to receiving androgen deprivation therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Leyh-Bannurah SR, Gazdovich S, Budäus L, et al. Local Therapy Improves Survival in Metastatic Prostate Cancer. Eur Urol. 2017. PMID: 28385454. doi:10.1016/j.eururo.2017.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。